Independent
Tenure on this board
9.6 yrs
Also a director at
Amgen Inc (AMGN)
12 nominees · 5 ballot items.
Election of 12 directors; advisory approval of named executive officer compensation; ratification of Deloitte & Touche LLP as independent auditor; shareholder proposal to create a Board Disability Access Committee; shareholder proposal to allow action by written consent.
Elect the 12 director nominees to serve until the 2027 Annual Meeting.
Non-binding, advisory approval of the company’s named executive officer compensation as disclosed in the proxy statement.
Ratify the appointment of Deloitte & Touche LLP as Boeing’s independent auditor for 2026.
Request to amend the company’s bylaws to establish a Board committee to oversee aircraft accessibility, assess compliance annually, and report findings to shareholders.
The shareholder proponent (National Center for Public Policy Research) requests a bylaw amendment creating a board-level Disability Access Committee to oversee aircraft accessibility, annual compliance assessment, and reporting to shareholders; management opposes, saying existing cross-functional teams, advisory groups, engineering leadership and collaborative industry engagement sufficiently address accessibility and that a separate board committee would be redundant and inefficient; the board recommends voting against citing potential administrative burden and that accessibility is integrated into current governance and safety processes.
Allow shareholders to act by written consent with the minimum number of votes necessary to authorize an action, without restrictions based on length of stock ownership.
The shareholder proponent (John Chevedden) seeks board action to permit shareholder written consent to enable shareholders meeting the minimum vote threshold to act without a meeting, arguing Boeing’s 25% special meeting threshold is too high and that written consent would enhance shareholder accountability; management opposes, citing risks of disenfranchisement, lack of transparency, potential manipulation by small groups, and that existing governance mechanisms sufficiently protect shareholders.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.47% | 51,005,657 | $10.2B |
| 2 | FMR LLC | 4.75% | 37,443,882 | $7.5B |
| 3 | STATE STREET CORP | 4.75% | 37,424,293 | $7.4B |
| 4 | Newport Trust Company, LLC | 3.64% | 28,664,824 | $5.7B |
| 5 | Capital World Investors | 3.26% | 25,727,803 | $5.1B |
| 6 | BlackRock, Inc. | 3.21% | 25,313,633 | $5.0B |
| 7 | BlackRock, Inc. | 2.03% | 16,040,620 | $3.2B |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.91% | 15,072,322 | $3.0B |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.65% | 13,039,407 | $2.6B |
| 10 | LOOMIS SAYLES CO L P | 1.56% | 12,266,456 | $2.4B |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.